Parkinson's Disease: Difference between revisions
Added information on D2 receptor agonists and physiotherapy |
m spelling mistake i made |
||
| Line 12: | Line 12: | ||
#[[Frontal cortex|Frontal cortex]] <span style="line-height: 1.5em">Tuberoinfundibular - </span>Arcuate nucleus to [[Pituitary gland|pituitary gland]] | #[[Frontal cortex|Frontal cortex]] <span style="line-height: 1.5em">Tuberoinfundibular - </span>Arcuate nucleus to [[Pituitary gland|pituitary gland]] | ||
<br> | |||
<u>'''Treatments'''</u> | |||
<u>'''Treatments'''</u> | |||
The [[Decarboxylase inhibitor|decarboxylase inhibitor]] – carbidopa, the </span>[[MAO|MAO inhibitor]]<span style="line-height: 1.5em">: Selegiline and </span>[[D2 receptor|D2 receptor agonists]]<span style="line-height: 1.5em"> like [[Bromocriptine|Bromocriptine]] can be used to treat Parkinson’s disease. | The [[Decarboxylase inhibitor|decarboxylase inhibitor]] – carbidopa, the </span>[[MAO|MAO inhibitor]]<span style="line-height: 1.5em">: Selegiline and </span>[[D2 receptor|D2 receptor agonists]]<span style="line-height: 1.5em"> like [[Bromocriptine|Bromocriptine]] can be used to treat Parkinson’s disease. | ||
</span><br> | </span><br> | ||
L-DOPA is a drug often given to patients in early stages of parkinsons disease to suppress symptoms. L-DOPA is converted to dopamine in the brain therefore increasing the amount available to bind to dopamine receptors<ref>Picture reference: Parkinsons Disease. National Institue of Environmental Health Sciences. Available from: http://www.niehs.nih.gov/health/topics/conditions/parkinson/ </ref><ref>http://www.nhs.uk/Conditions/Parkinsons-disease/Pages/Introduction.aspx</ref>. | |||
[[D2 receptor agonists|D2 receptor agonists]], such as [[Bromocriptine|Bromocriptine]] and Cabergoline, are also prescribed to sufferers of Parkinson's disease. D2 receptor agonists, unlike L-DOPA, actually mimic [[Dopamine|dopamine]]. This therefore reduces the symptoms that patients with Parkinson's disease experience, a major one being [[Bradykinesia|bradykinesia]]. There are more known side effects associated with [[D2 receptor agonists|D2 receptor agonists]] compared to L-DOPA and so L-DOPA is more commonly prescribed to patients<ref>Health Talk. Dopamine receptor agonists. 2016 [cited 1/12/16]; Available from http://www.healthtalk.org/peoples-experiences/nerves-brain/parkinsons-disease/dopamine-receptor-agonists</ref>. | |||
Additionally, sufferers of Parkinson's disease can receive [[Physiotherapy|physiotherapy]] to reduce the severity of their motor symptoms. Physiotherapists can introduce the patient to a wide range of exercises which can strengthen their [[Muscles|muscles]] and improve flexibility. Manual physiotherapy invovles massaging different regions of the body to stimulate movement<ref>National Parkinson Foundation. Understanding Parkinsons. 2016 [cited 1/12/16]; Available from http://www.parkinson.org/understanding-parkinsons</ref>. | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | <br> | ||
<br> | |||
<br> | |||
=== References === | === References === | ||
<references /> | <references /> | ||
Revision as of 20:12, 4 December 2016
Parkinson’s disease, also known as hypokinetic rigid syndrome (HRS), is an idiopathic and has no known cause. It is normally due to the degeneration of dopaminergic neurones of the nigrostriatal tract and loss of dopamine (DA) neurotransmission in the striatum. The symptoms of this disease are a resting tremor, muscle rigidity, suppression of voluntary movements (hypokinesis) and postural instability. Another common symptom of parkinsons disease is freezing which is the inability to move temporarily and can last a few seconds to several minutes. Often people feel like their feet are stuck to the ground and this occurs often when a sufferer is carrying out repetitive movements like walking, eating or writing.
In the later stages, mental and behavioural symptoms may occur such as anxiety, depression, anosmis, difficultly sleeping and even things such as dementia.
The main 4 dopaminergic pathways are:-
- Nigrostriatal - Substantia nigra to striatum
- Striatum Mesolimbic - Ventral tegmental area to nucleus accumbens
- Mesocortical - Ventral tegmental area to frontal cortex
- Frontal cortex Tuberoinfundibular - Arcuate nucleus to pituitary gland
Treatments
The decarboxylase inhibitor – carbidopa, the </span>MAO inhibitor: Selegiline and D2 receptor agonists like Bromocriptine can be used to treat Parkinson’s disease.
L-DOPA is a drug often given to patients in early stages of parkinsons disease to suppress symptoms. L-DOPA is converted to dopamine in the brain therefore increasing the amount available to bind to dopamine receptors[1][2].
D2 receptor agonists, such as Bromocriptine and Cabergoline, are also prescribed to sufferers of Parkinson's disease. D2 receptor agonists, unlike L-DOPA, actually mimic dopamine. This therefore reduces the symptoms that patients with Parkinson's disease experience, a major one being bradykinesia. There are more known side effects associated with D2 receptor agonists compared to L-DOPA and so L-DOPA is more commonly prescribed to patients[3].
Additionally, sufferers of Parkinson's disease can receive physiotherapy to reduce the severity of their motor symptoms. Physiotherapists can introduce the patient to a wide range of exercises which can strengthen their muscles and improve flexibility. Manual physiotherapy invovles massaging different regions of the body to stimulate movement[4].
References
- ↑ Picture reference: Parkinsons Disease. National Institue of Environmental Health Sciences. Available from: http://www.niehs.nih.gov/health/topics/conditions/parkinson/
- ↑ http://www.nhs.uk/Conditions/Parkinsons-disease/Pages/Introduction.aspx
- ↑ Health Talk. Dopamine receptor agonists. 2016 [cited 1/12/16]; Available from http://www.healthtalk.org/peoples-experiences/nerves-brain/parkinsons-disease/dopamine-receptor-agonists
- ↑ National Parkinson Foundation. Understanding Parkinsons. 2016 [cited 1/12/16]; Available from http://www.parkinson.org/understanding-parkinsons